COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
16 hedge funds and large institutions have $1.53M invested in COSCIENS Biopharma Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
60% more funds holding
Funds holding: 10 → 16 (+6)
24% more capital invested
Capital invested by funds: $1.24M → $1.53M (+$296K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.18M |
| 2 |
TCM
Tenor Capital Management
New York
|
+$477K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$199K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$97.5K |
| 5 |
Two Sigma Investments
New York
|
+$23.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$84K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$42.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$37.8K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$8K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$7K |
CSCI Hedge Fund Activity: Q3 2015 in Review
16 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2015, worth a combined $1.53M — up 24% from $1.24M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CSCI positions and 3 closed out — a net gain of 6 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.18M. The largest seller was Nine Chapters Capital Management, exiting entirely with an estimated $84K sold.
- 16 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2015, up from 10 in Q2 2015.
- Funds reported $1.53M of COSCIENS Biopharma Inc. Common Stock stock for Q3 2015, up 24% quarter-over-quarter.
- 9 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2015 and 3 closed out, a net change of +6 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2015 was Renaissance Technologies, an estimated $1.18M added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2015 was Nine Chapters Capital Management, an estimated $84K sold.
Based on aggregated 13F filings for Q3 2015.